In March 2021, FujiFilm Diosynth Biotechnologies announced a $2B manufacturing site in Holly Springs, NC.

When it opens in 2025, the facility will develop, produce, package and ship medicines approved by the Food and Drug Administration and other regulatory bodies throughout the U.S. and the world. Its 725 high-quality jobs will include those for scientists, quality control workers and supply chain experts. This facility will be the largest cell culture CDMO biopharmaceutical manufacturing facility in North America, focused on sustainability.

The FDB Holly Springs site’s ambition is to be an industry leader, innovating sustainably with a lasting impact and for the betterment of FDB, Life Sciences, and the environment at large.

Join us to hear from Matt Kuntz, ESG and Sustainability Project Manager (top photo), and Sarah Gaskill, Head of Sustainability and ESG (bottom photo) for FujiFilm Diosynth Biotechnologies. Matt and Sarah are excited to share insight on the sustainability journey FujiFilm Diosynth Biotechnologies is embarking on.